Agribusiness, Agriculture, Veterinary Medicine, Cassava, Garri, food security, Agritech and the Red Meat Value Chain.
Showing posts with label favipiravir. Show all posts
Showing posts with label favipiravir. Show all posts
Wednesday, January 20, 2016
Antiviral favipiravir successfully treats Lassa virus in guinea pigs.
Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study. Lassa fever is endemic to West Africa and affects about 300,000 people annually, killing roughly 5,000. In some parts of Sierra Leone and Liberia, it is believed nearly 15 percent of people admitted to hospitals have Lassa fever, according to the Centers for Disease Control and Prevention. No vaccine or licensed treatment exists for Lassa fever, although ribavirin, licensed for hepatitis C treatment, has been used with limited success. In the new study, published Oct. 12, 2015, in Scientific Reports, favipiravir not only effectively treated guinea pigs infected with Lassa virus, it also worked better than ribavirin.
Two days after infecting groups of guinea pigs with a lethal dose of Lassa virus, the scientists treated the rodents daily for two weeks with either ribavirin, low doses of favipiravir, or high doses of favipiravir. They also evaluated the effect of high-dose favipiravir in the rodents that began treatment five, seven or nine days after infection. All of the animals that received high-dose favipiravir were completely protected from lethal infection; animals treated seven or nine days after infection had begun showing signs of disease, but their conditions quickly improved when treatment began. Those animals in the low-dose favipiravir group showed mild to moderate signs of disease, but those symptoms resolved after about one week of treatment. The animals treated with ribavirin appeared normal during the treatment phase but developed severe disease shortly after treatment ended.
Further testing and human clinical trials are needed to determine if favipiravir, also known as T-705 and Avigan, could effectively treat Lassa virus infection in people.
Story source;NIH/National Institute of Allergy and Infectious Diseases.
Subscribe to:
Posts (Atom)
Agribusiness ideas.
Popular Posts
-
513 million tons of additional food production guaranteed- AfDB.The African Development Bank (AfDB) has developed a new initiative called ...
-
The Faroe Islands have some of the most beautiful roads in the world. It is impossible to describe what it feels like driving through t...
-
Five ways agriculture could benefit from artificial intelligence. Agriculture is the industry that accompanied the evolution of humanity ...
-
Digital technology has made its way into various industries but its impact in agriculture has the highest advantages with food security bei...
-
Germany culling some 77,000 poultry as bird flu found on farms The culling of about 77,000 turkeys, chickens and ducks is underway after b...
-
LlamaZOO to Unveil World’s First Virtual Reality Canine Dissection at 2017 Western Veterinary Conference, Las Vegas. LlamaZOO Interactive...
AGRIBUSINESS EDUCATION.
Translate
I-CONNECT -AGRICULTURE
AGRIBUSINESS TIPS.
AGRIBUSINESS.
The Agriculture Daily
veterinarymedicineechbeebolanle-ojuri.blogspot.com Cassava: benefits of garri as a fermented food. Cassava processing involves fermentation which is a plus for gut health. The fermentation process removes the cyanogenic glucosides present in the fres...